Current Report Filing (8-k)
August 01 2017 - 5:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
August 1, 2017
ADVANCED
MEDICAL ISOTOPE CORPORATION
(Exact
name of Registrant as specified in its Charter)
Delaware
|
|
00-53497
|
|
80-0138937
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File No.)
|
|
(IRS
Employer
Identification
No.)
|
719
Jadwin Avenue, Richland, WA 99352
(Address
of principal executive offices)
(509)
736-4000
(Registrant’s
Telephone Number)
Not
Applicable
(Former
name or address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
[ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[ ]
Item
7.01 Regulation FD Disclosure.
On
August 1, 2017,
Advanced Medical Isotope Corporation (the “
Company
”)
held a shareholder update webcast. In connection with the webcast, the Company used presentation materials, furnished as Exhibit
99.1 hereto, which is incorporated herein by reference.
In
accordance with General Instruction B.2 for Form 8-K, the information in this Form 8-K, including Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “
Exchange Act
”),
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
See
Exhibit Index.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ADVANCED
MEDICAL ISOTOPE CORP.
|
|
|
|
Date:
August 1, 2017
|
By:
|
/s/
L. Bruce Jolliff
|
|
|
L.
Bruce Jolliff
|
|
|
Chief
Financial Officer
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Corporate
presentation materials, dated August 1, 2017.
|
Vivos (QB) (USOTC:RDGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vivos (QB) (USOTC:RDGL)
Historical Stock Chart
From Sep 2023 to Sep 2024